SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

SAN

82.08

+1.41%↑

SHL.DE

42.36

+0.19%↑

PHIA

27.11

+0.82%↑

SRT3

239.4

+0.59%↑

ORNBV.FI

67.7

0%↓

Home・Aandelen Lijst・Nanobiotix

N
Nanobiotix

Gesloten

25.55 11.33

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.1

Max

25.6

Belangrijke statistieken
By Trading Economics
Inkomsten	-5.4M
Verkoop	27M
Winstmarge	-20.208
Werknemers	103
EBITDA	1.1M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+0.22% upside

Dividenden
By Dow Jones
Volgende Winsten	1 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1B
Vorige openingsprijs	14.22
Vorige sluitingsprijs	25.55

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

2.975 / 3.015 Steun & Weerstand

Nanobiotix Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 feb 2026, 23:53 UTC

Populaire aandelen

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 feb 2026, 17:55 UTC

Populaire aandelen

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 feb 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb 2026, 23:33 UTC

Acquisities, Fusies, Overnames

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

27 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

27 feb 2026, 21:30 UTC

Winsten

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb 2026, 21:30 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb 2026, 21:17 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 21:10 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb 2026, 21:09 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb 2026, 21:00 UTC

Winsten

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 feb 2026, 20:31 UTC

Acquisities, Fusies, Overnames

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 feb 2026, 20:24 UTC

Marktinformatie

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 feb 2026, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 feb 2026, 20:12 UTC

Marktinformatie

Nike Seen With Further Challenges in China -- Market Talk

27 feb 2026, 19:44 UTC

Marktinformatie

Gold Caps Historic Month -- Market Talk

27 feb 2026, 19:39 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 19:38 UTC

Winsten

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 feb 2026, 18:53 UTC

Acquisities, Fusies, Overnames

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 feb 2026, 18:45 UTC

Winsten

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 feb 2026, 18:45 UTC

Marktinformatie

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 feb 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

27 feb 2026, 17:07 UTC

Winsten

Pemex Cuts 4Q Loss As Operating Results Improve

27 feb 2026, 17:00 UTC

Marktinformatie

Corn Rides Oil Momentum Higher -- Market Talk

27 feb 2026, 16:31 UTC

Marktinformatie

Canadian Economy Shows Resilience -- Market Talk

27 feb 2026, 16:17 UTC

Marktinformatie

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 feb 2026, 15:49 UTC

Winsten

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Peer Vergelijking

Prijswijziging

Nanobiotix Prognose

Koersdoel

By TipRanks

0.22% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 23 EUR 0.22%

Hoogste 23 EUR

Laagste 23 EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Nanobiotix - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Nanobiotix - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

2.975 / 3.015Steun & Weerstand

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.